| Name | Title | Contact Details |
|---|
A new setpoint for immunometabolism
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
BioVision is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oncocyte’s mission is to provide tests to physicians and patients that provide answers at critical decision points during lung cancer diagnosis.
Bioinformatics.org is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.